Clinical Sciences Core (Core C)
临床科学核心(核心 C)
基本信息
- 批准号:10404935
- 负责人:
- 金额:$ 25.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AIDS clinical trial groupAIDS/HIV problemAcademic Medical CentersAcquired Immunodeficiency SyndromeAgreementApplications GrantsAwardBiologicalCaringCenters for Disease Control and Prevention (U.S.)ClinicClinicalClinical ResearchClinical SciencesCollaborationsCommunitiesComprehensive Health CareConsultationsCountyCoupledDataData Science CoreData SetDatabasesDevelopmentDoctor of PhilosophyEnvironmentEpidemicEpidemiologyExtramural ActivitiesFosteringFoundationsFundingGoalsGrantHIVHIV InfectionsHIV-1HIV/HCVHarm ReductionHealthHepatitis C virusInfectionInfrastructureInstitutionInvestigationJointsLawsLeadershipManuscriptsMissionModelingOutcomeParticipantPatient RecruitmentsPersonsPoliciesPostpartum PeriodPrevalenceProcessPublicationsPublishingResearchResearch DesignResearch PersonnelResearch Project GrantsResearch SupportResourcesRiskRisk AssessmentScienceScientistServicesSoutheastern United StatesSpecimenSupport GroupsTennesseeTimeTissuesTranslational ResearchUnited States National Institutes of HealthWomanWorkagedbasecareercareer developmentcohortcommunity based participatory researchdatabase designmalemedical schoolsnext generationprogramsrecruitresearch studyresponserural areasuccessurban areavolunteer
项目摘要
Clinical Sciences Core – PROJECT SUMMARY
The Tennessee Center for AIDS Research (CFAR) is located in the Southeastern US, the region with both the
greatest number of new HIV-1 infections, and of persons living with HIV. The CFAR is a four-way partnership
between a research-intensive institution (Vanderbilt University Medical Center), a historically black medical
college (Meharry Medical College), an academically engaged state health department (Tennessee Department
of Health), and an highly evolved HIV-focused community-based organization (Nashville CARES). This CFAR's
institutional and community environment is rich in opportunity, and with a culture of engagement and
collaboration. The Clinical Sciences Core (CSC) fills major gaps in the local research environment, and in so
doing supports the mission of the CFAR to reduce the overall burden of HIV/AIDS through the pursuit of National
Institutes of Health high priorities for HIV/AIDS research, with the ultimate goal of ending the HIV epidemic.
Access to research study participants and associated biospecimens, and to large clinical cohort datasets, are
essential for high-quality clinical and translational HIV research. Since this CFAR was established in 2015, the
CSC has been integral to its success. The CSC is essential for early stage investigators on their path toward
independent extramural funding, which equips the next generation of research scientists while also serving to
expand this CFAR's HIV research portfolio and funding base. Building upon the expertise and collective
infrastructure of the CFAR, coupled with the addition of a strong, established community partner in CARES, we
will pursue the following three specific aims: 1) To propel the use of observational databases for high impact HIV
clinical and translational research; 2) To support research projects that require access to study volunteers and
associated biological specimens, and; 3) To support research opportunities for MMC investigators, including team
science.
临床科学核心-项目总结
田纳西州艾滋病研究中心(CFAR)位于美国东南部,该地区既有
艾滋病毒1型新感染者和艾滋病毒感染者人数最多。CFAR是一个四方合作伙伴关系
在一个研究密集型机构(范德比尔特大学医学中心),一个历史上的黑人医学中心和一个研究中心之间,
学院(梅哈里医学院),一个学术从事国家卫生部门(田纳西州部
以及一个高度发展的以艾滋病毒为重点的社区组织(纳什维尔CARES)。这个CFAR
机构和社区环境充满机会,并具有参与和
协作临床科学核心(CSC)填补了当地研究环境的主要空白,
这样做支持CFAR的使命,即通过追求国家艾滋病毒/艾滋病的总体负担,
卫生研究所高度重视艾滋病毒/艾滋病研究,最终目标是结束艾滋病毒的流行。
访问研究参与者和相关生物标本以及大型临床队列数据集,
这对于高质量的临床和转化HIV研究至关重要。自2015年成立以来,
CSC是其成功不可或缺的因素。CSC是必不可少的早期阶段的研究人员在他们的道路上,
独立的校外资金,这装备下一代的研究科学家,同时也服务于
扩大CFAR的艾滋病毒研究组合和资金基础。利用专业知识和集体
CFAR的基础设施,加上CARES中强大的,成熟的社区合作伙伴,我们
将追求以下三个具体目标:1)推动使用高影响力的艾滋病毒观察数据库
临床和转化研究; 2)支持需要获得研究志愿者的研究项目,
相关生物标本; 3)支持MMC研究者的研究机会,包括团队
科学
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David W Haas其他文献
David W Haas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David W Haas', 18)}}的其他基金
Vanderbilt CTU SARS-CoV-2 Supplement
范德比尔特 CTU SARS-CoV-2 补充品
- 批准号:
10166023 - 财政年份:2020
- 资助金额:
$ 25.4万 - 项目类别: